Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • Drake
    Member
    • Apr 2009
    • 10

    #1

    GAGE update and result analysis

    Hi,
    I have recently started to use gage and I am bit confused about the pathway results data.

    1) My pathway results after running gage contain 114 pathways (80 of them are NA); however, when I look online at the KEGG website, I find 120 pathways for my organism. Isn't gage able to use the latest version of online data?

    2) My greater and less data contains the same list of pathways .. just in inverse order (but completely different p/q values). However, this is a bit confusing: e.g. my differential expressed gene list does not contain any down-regulated genes for one pathway but only contains genes that are up-regulated in the same pathway. Why do these pathways even appear in the less dataset when there is no single gene down-regulated? Since the p/q values are too high, I will discard the pathway anyways - was just wondering why this is listed. And what's the purpose of listing them if all q-values are similar: e.g. 0.9929488953. In this context, what's a general excepted q-value cut-off when it comes to publishing data? Is 0.2 or even 0.5 still accepted?

    3) Are pathways with a set.size lower than 10 not considered in the stats?

    Any feedback is appreciated! Thanks
  • bigmw
    Senior Member
    • Aug 2013
    • 124

    #2
    gage does use the latest data from KEGG if you generate gene set data using kegg.gsets() function. However, the reference pathway list could be out of date. The reason you see NA for 80 pathways is that those pathways are out of the set.size range. In other words, they may have too few genes mapped, hence no gene set test were done on them.
    The greater and less elements in the result list correspond to up and down regulation test on all pathways (gene sets), not just the significant ones. You want to go though the gage function documentation for details, something like:
    ?gage

    Comment

    Latest Articles

    Collapse

    • SEQadmin2
      Beyond CRISPR/Cas9: Understand, Choose, and Use the Right Genome Editing Tool
      by SEQadmin2



      CRISPR/Cas9 sparked the gene editing revolution for both research and therapeutics.1 But this system still showed severe issues that limited its applications. The most prominent were the heavy reliance on PAM sequences, delivery limitations, double-stranded breaks that prompt unintended edits and cell death, and editing inefficiency (both in targeting and in knock-in reliability).

      Despite this, “CRISPR helped turn genome editing from a specialized technique into
      ...
      07-31-2026, 11:01 AM
    • SEQadmin2
      Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
      by SEQadmin2


      Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

      The systematic characterization of the human proteome has
      ...
      07-20-2026, 11:48 AM

    ad_right_rmr

    Collapse

    News

    Collapse

    Topics Statistics Last Post
    Started by SEQadmin2, Yesterday, 12:22 PM
    0 responses
    12 views
    0 reactions
    Last Post SEQadmin2  
    Started by SEQadmin2, 08-11-2026, 10:35 AM
    0 responses
    13 views
    0 reactions
    Last Post SEQadmin2  
    Started by SEQadmin2, 08-06-2026, 07:41 AM
    0 responses
    30 views
    0 reactions
    Last Post SEQadmin2  
    Started by SEQadmin2, 08-03-2026, 10:13 AM
    0 responses
    48 views
    0 reactions
    Last Post SEQadmin2  
    Working...